A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
Clinical trial NCT06868212 · RECRUITING
Trial details
- NCT number
- NCT06868212
- Sponsor
- Novartis Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-11
- Primary completion
- 2027-02-22
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.